Video

Dr. Grunwald on Preventing Relapse in Lymphoid and Myeloid Malignancies

Michael R. Grunwald, MD, FACP, discusses preventing relapse in patients with lymphoid and myeloid malignancies following allogeneic transplantation.

Michael R. Grunwald, MD, FACP, a clinical assistant professor of medicine at the University of North Carolina, as well as a hematologist/oncologist at Levine Cancer Institute, Atrium Health, discusses preventing relapse in patients with lymphoid and myeloid malignancies following allogeneic transplantation.

Several ongoing efforts seek to prevent relapse in patients with myeloid and lymphoid malignancies, according to Grunwald. Many of these strategies incorporate targeted agents after transplantation. For example, in patients who have FLT3 mutations, or those with leukemia harboring a Philadelphia chromosome, a targeted inhibitor will be utilized following transplantation, Grunwald says.

However, a prospective study demonstrating an advantage for a targeted inhibitor after transplant has yet to be conducted. Currently, an ongoing study in patients with FLT3 mutations is examining the use of gilteritinib (Xospata) vs placebo after transplantation, the results of which are anticipated, Grunwald concludes.

Related Videos
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss ongoing research to watch in acute lymphoblastic leukemia.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss how to incorporate blinatumomab into clinical practice for ALL.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss adverse effect management in acute lymphoblastic leukemia.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss data for blinatumomab plus chemotherapy in newly diagnosed pediatric ALL.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss first-line treatment considerations for pediatric ALL.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on blinatumomab as consolidation therapy in older patients with newly diagnosed ALL.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on alloHCT outcomes from the ECOG ACRIN E1910 trial of blinatumomab.
Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
Phase 3 AMPLIFY Trial
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, highlight key data in CML and ALL presented at the 2024 ASH Annual Meeting.